Apalutamide treatment of locally advanced prostate cancer

• Authors: Maria Palasik

Abstracts

EN

Prostate cancer is most commonly diagnosed cancer in men. The choice of treatment method depends on many factors: the patient’s age, other patient’s diseases, psychophysical status and expected survival time. Hormonotherapy plays very important role in patients with no possible radical treatment. New therapies apply in patients with castration-resistant metastatic prostate cancer. First registered drug in patients with biochemical progression without metastases is apalutamide.

Keywords

EN

prostate cancer; castration resistance; hormonotherapy; apalutamide

• Publisher: Medical Education
• Journal: OncoReview
• Year: 2023
• Volume: 13
• Issue: 1
• Pages: 31-32

Dates

published

2023

Contributors

author

Maria Palasik

• Provincial Center of Oncology in Gdansk

References

• Krajowy Rejestr Nowotworów 2021 r.
• Smith MR, Saad F, Chowdhury S et al. Apalutamide and Overall Survival in Prostate Cancer. Eur Urol. 2021; 79(1): 150-8.

Identifiers

DOI

10.24292/01.OR.131315323

Biblioteka Nauki

22676859